Download PDF
J Pediatr Infect Dis 2015; 10(01): 003-011
DOI: 10.1055/s-0035-1554969
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Serum Procalcitonin Assay for Investigations and Clinical Management of Neonatal Sepsis: A Review

Idris Abdullahi Nasir
1   Department of Medical Microbiology, University of Abuja Teaching Hospital, Abuja, Nigeria
,
Hadiza Umar Mele
2   Clinical Laboratory Unit, National Board for Technical Education, Kaduna State, Nigeria
,
Adamu Babayo
3   Department of Medical Laboratory Sciences, University of Maiduguri, Maiduguri, Nigeria
,
Fatima Yahaya
2   Clinical Laboratory Unit, National Board for Technical Education, Kaduna State, Nigeria
› Author Affiliations
Further Information

Publication History

24 September 2014

27 November 2014

Publication Date:
03 July 2015 (online)

   Permissions and Reprints

Abstract

The diagnosis and management of sepsis are very challenging especially in pediatric cases where the clinical criteria for the diagnosis overlap with nonbacterial etiologies of systemic inflammation. Initiation of antibiotic therapy for sepsis is necessary although the diagnostic evaluation is ongoing because delayed antibiotic therapy is associated with increased mortality. A highly sensitive and specific biomarker, such as procalcitonin, that improves decisions about initiating, discontinuing, or changing antibiotic therapy could have substantial clinical benefits of managing neonatal sepsis. This is a review of relevant published articles using extensive literature search made through google, PubMed/Medline, NLM, Scopus, and HINARI on randomized controlled and observational studies of procalcitonin-based diagnosis and antimicrobial-guided therapy especially in neonatal sepsis. Our systematic review found that procalcitonin-guided diagnosis, need for antibiotics, treatment evaluation give better outcome and prognosis than any other biomarker that were hitherto utilized in neonatal sepsis. Now that sepsis especially in children has become a frequent medical emergency, there is a need to extensively evaluate and possibly consider serum procalcitonin as an adjunctive marker to be combined with other commonly used approaches such as blood culture, full blood count, and differentials in order to enhance prompt and rational clinical management before blood culture results are available.

Keywords

procalcitonin - sepsis - biomarker - diagnosis - neonates
 

  • References

  • 1 Chacko B, Sohi I. Early onset neonatal sepsis. Indian J Pediatr 2005; 72 (1) 23-26
    CrossrefPubMedGoogle Scholar
  • 2 Antia-Obong OE, Utsalo SJ, Udo JJ, Udo KT. Neonatal septicaemia in Calabar, Nigeria. Cent Afr J Med 1992; 38 (4) 161-165
    PubMedGoogle Scholar
  • 3 Omene JA. Neonatal septicaemia in Benin City, Nigeria. A review of 74 cases. Trop Geogr Med 1979; 31 (1) 35-39
    PubMedGoogle Scholar
  • 4 Klein JO, Marcy MS, Bacterial Sepsis and Meningitis. In Infectious Diseases of the Fetus and the Newborn. Edited by Remington JJ, Klein JO. Philadelphia: WB Sauders Co; 1995: 835-890
    Google Scholar
  • 5 Sankar MJ, Agarwal R, Deorari AK, Paul VK. Sepsis in the newborn. Indian J Pediatr 2008; 75 (3) 261-266
    CrossrefPubMedGoogle Scholar
  • 6 Al-Zwaini EJ. Neonatal septicaemia in the neonatal care unit, Al-Anbar governorate, Iraq. East Mediterr Health J 2002; 8 (4-5) 509-514
    PubMedGoogle Scholar
  • 7 Amiebenomo CS, Yakubu AM, Bello CSS, Ewa B. Neonatal Septicaemia in Zaria. Niger Med J 1988; 18: 349-351
    PubMedGoogle Scholar
  • 8 Edwards MS. Postnatal Bacterial Infections. In Neonatal Perinatal Medicine: Diseasesm of the Fetus and Infants. 7th edition. Edited by Fanaroff AA, Martin RJ. St Louis, MO: CV Mosby; 2002: 706-726
    Google Scholar
  • 9 Placzek MM, Whitelaw A. Early and late neonatal septicaemia. Arch Dis Child 1983; 58 (9) 728-731
    CrossrefPubMedGoogle Scholar
  • 10 Motara F, Ballot DE, Perovic O. Epidemiology of neonatal sepsis at Johannesburg Hospital. Southern Afr. J Epidemiol Infect 2005; 20 (3) 90-93
    PubMedGoogle Scholar
  • 11 Whitney CG, Farley MM, Hadler J , et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343 (26) 1917-1924
    CrossrefPubMedGoogle Scholar
  • 12 Roberts RR, Hota B, Ahmad I , et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49 (8) 1175-1184
    CrossrefPubMedGoogle Scholar
  • 13 Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011; 6 (Suppl. 01) S4-S15
    CrossrefPubMedGoogle Scholar
  • 14 Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181 (1) 176-180
    CrossrefPubMedGoogle Scholar
  • 15 Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30 (3) 556-573
    CrossrefPubMedGoogle Scholar
  • 16 Christ-Crain M, Müller B. Procalcitonin in bacterial infections—hype, hope, more or less?. Swiss Med Wkly 2005; 135 (31-32) 451-460
    PubMedGoogle Scholar
  • 17 Linscheid P, Seboek D, Zulewski H, Keller U, Müller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005; 146 (6) 2699-2708
    CrossrefPubMedGoogle Scholar
  • 18 Becker KL, Nylén ES, White JC, Müller B, Snider Jr RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89 (4) 1512-1525
    CrossrefPubMedGoogle Scholar
  • 19 Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection 2007; 35 (5) 352-355
    CrossrefPubMedGoogle Scholar
  • 20 Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B ; Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011; 37 (2) 384-392
    CrossrefPubMedGoogle Scholar
  • 21 Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34 (10) 2596-2602
    CrossrefPubMedGoogle Scholar
  • 22 Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010; 8 (5) 575-587
    CrossrefPubMedGoogle Scholar
  • 23 Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323 (1-2) 17-29
    CrossrefPubMedGoogle Scholar
  • 24 Ming J, Adil IK. Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. LabMedcine 2010; 41: 173-177
    PubMedGoogle Scholar
  • 25 The WHO Young Infants Study Group. Serious infections in young infants in developing countries: rationale for a multicenter study. Pediatr Infect Dis J 1999; 18 (10, Suppl): S4-S7
    CrossrefPubMedGoogle Scholar
  • 26 Dawodu A, Twum-Danso K, Al Umran K. A case control study of neonatal sepsis: experience from Saudi Arabia. J Trop paed 1997; 43: 84-88
    PubMedGoogle Scholar
  • 27 World Health Organization. Perinatal mortality. Report No: WHO/FRH/MSM/967. Geneva: WHO; 1996
    Google Scholar
  • 28 Jumah DS, Hassan MK. Predictors of mortality outcome in neonatal sepsis. Med J Basrah Univ 2007; 25: 11-18
    PubMedGoogle Scholar
  • 29 Costello A, Francis V, Byrne A. The state of the world's newborns. Washington: Save the Children Fund; 2001. 411. 1929-1934
    Google Scholar
  • 30 Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT. Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal Ed 2005; 90 (3) F220-F224
    CrossrefPubMedGoogle Scholar
  • 31 Ako-Nai AK, Adejuyigbe EA, Ajayi FM, Onipede AO. The bacteriology of neonatal septicaemia in Ile-Ife, Nigeria. J Trop Pediatr 1999; 45 (3) 146-151
    CrossrefPubMedGoogle Scholar
  • 32 Anah MU, Udo JJ, Ochigbo SO, Abia-Bassey LN. Neonatal septicaemia in Calabar, Nigeria. Trop Doct 2008; 38 (2) 126-128
    CrossrefPubMedGoogle Scholar
  • 33 Marshall JC, Reinhart K ; International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009; 37 (7) 2290-2298
    CrossrefPubMedGoogle Scholar
  • 34 Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009; 37 (6) 497-507
    CrossrefPubMedGoogle Scholar
  • 35 Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007; 50 (1) 34-41
    CrossrefPubMedGoogle Scholar
  • 36 Dandona P, Nix D, Wilson MF , et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79 (6) 1605-1608
    CrossrefPubMedGoogle Scholar
  • 37 Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159 (2) 253-264
    CrossrefPubMedGoogle Scholar
  • 38 Summary of B.R.A.H.M.S PCT sensitive KRYPTOR® Test System. Available at: www.accessdata.fda.gov/cdrh_docs/pdf7/K070310.pdf . Accessed September 18, 2014
    PubMedGoogle Scholar
  • 39 Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007; 39 (4) 383-390
    CrossrefPubMedGoogle Scholar
  • 40 Bone RC, Balk RA, Cerra FB , et al; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101 (6) 1644-1655
    CrossrefPubMedGoogle Scholar
  • 41 Summary of VIDAS B.R.A.H.M.S PCT Assay. Available at: www.accessdata.fda.gov/cdrh_docs/pdf7/K071146.pdf . Accessed September 18, 2014
    PubMedGoogle Scholar
  • 42 Müller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 2001; 131 (41-42) 595-602
    PubMedGoogle Scholar
  • 43 Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine 2000; 12 (6) 762-764
    CrossrefPubMedGoogle Scholar
  • 44 Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010; 97 (2) 165-174
    CrossrefPubMedGoogle Scholar
  • 45 Raimondi F, Ferrara T, Maffucci R , et al. Neonatal sepsis: a difficult diagnostic challenge. Clin Biochem 2011; 44 (7) 463-464
    CrossrefPubMedGoogle Scholar
  • 46 Joram N, Boscher C, Denizot S , et al. Umbilical cord blood procalcitonin and C reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection. Arch Dis Child Fetal Neonatal Ed 2006; 91 (1) F65-F66
    PubMedGoogle Scholar
  • 47 Savagner C, Leboucher B, Gascoin-Lachambre G, Gras-Leguen C. Relevance of procalcitonin for the diagnosis of early and late-onset sepsis in newborns. In: Luciano Azevedo ed. Sepsis - An Ongoing and Significant Challenge. InTech; 2012: 250-258
    Google Scholar
  • 48 Altunhan H, Annagür A, Örs R, Mehmetoğlu I. Procalcitonin measurement at 24 hours of age may be helpful in the prompt diagnosis of early-onset neonatal sepsis. Int J Infect Dis 2011; 15 (12) e854-e858
    CrossrefPubMedGoogle Scholar
  • 49 Stocker M, Hop WC, van Rossum AM. Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study. BMC Pediatr 2010; 10: 89
    CrossrefPubMedGoogle Scholar
  • 50 Whang KT, Vath SD, Becker KL , et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 2000; 14 (1) 73-78
    CrossrefPubMedGoogle Scholar
  • 51 Summary of Safety and Effectiveness. B.R.A.H.M.S PCT LIA. Available at: www.accessdata.fda.gov/cdrh_docs/pdf4/K040887.pdf . Accessed September 18, 2014
    PubMedGoogle Scholar
  • 52 Christ-Crain M, Stolz D, Bingisser R , et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174 (1) 84-93
    CrossrefPubMedGoogle Scholar
  • 53 Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype?. Swiss Med Wkly 2009; 139 (23-24) 318-326
    PubMedGoogle Scholar
  • 54 Krüger S, Ewig S, Papassotiriou J , et al; CAPNETZ Study Group. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009; 10: 65
    CrossrefPubMedGoogle Scholar
  • 55 Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34 (7) 1996-2003
    CrossrefPubMedGoogle Scholar
  • 56 Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006; 10 (5) R145
    CrossrefPubMedGoogle Scholar
  • 57 Schuetz P, Affolter B, Hunziker S , et al. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest 2010; 40 (4) 376-381
    CrossrefPubMedGoogle Scholar
  • 58 Jensen JU, Hein L, Lundgren B , et al; Procalcitonin and Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39 (9) 2048-2058
    CrossrefPubMedGoogle Scholar
  • 59 Schumm J, Pfeifer R, Ferrari M, Kuethe F, Figulla HR. An unusual case of progressive shock and highly elevated procalcitonin level. Am J Crit Care 2010; 19 (1) 96-3
    CrossrefPubMedGoogle Scholar
  • 60 Sabat R, Höflich C, Döcke WD , et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 2001; 27 (6) 987-991
    CrossrefPubMedGoogle Scholar
  • 61 Brodska H, Drabek T, Malickova K , et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 2009; 13 (2) R37
    CrossrefPubMedGoogle Scholar
  • 62 Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009; 42 (7-8) 725-728
    CrossrefPubMedGoogle Scholar
  • 63 Baylan O, Balkan A, Inal A , et al. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 2006; 59 (3) 164-167
    PubMedGoogle Scholar
  • 64 Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41 (6) 832-840
    CrossrefPubMedGoogle Scholar
  • 65 Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 39 (7) 1792-1799
    CrossrefPubMedGoogle Scholar
  • 66 Schuetz P, Christ-Crain M, Albrich W, Zimmerli W, Mueller B ; ProHOSP Study Group. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence 2010; 1 (2) 88-92
    CrossrefPubMedGoogle Scholar
  • 67 Steinbach G, Rau B, Debard AL , et al. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 2004; 42 (4) 440-449
    CrossrefPubMedGoogle Scholar
  • 68 Hubl W, Krassler J, Zingler C , et al. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 2003; 49 (7-8) 319-327
    PubMedGoogle Scholar
  • 69 de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M. Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. Clin Chem 2009; 55 (5) 1043-1044
    CrossrefPubMedGoogle Scholar
  • 70 Schuetz P, Christ-Crain M, Huber AR, Müller B. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. Clin Biochem 2010; 43 (3) 341-344
    CrossrefPubMedGoogle Scholar
  • 71 Stolz D, Smyrnios N, Eggimann P , et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34 (6) 1364-1375
    CrossrefPubMedGoogle Scholar
  • 72 Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177 (5) 498-505
    CrossrefPubMedGoogle Scholar
  • 73 Hochreiter M, Köhler T, Schweiger AM , et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009; 13 (3) R83
    CrossrefPubMedGoogle Scholar
  • 74 Schroeder S, Hochreiter M, Koehler T , et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009; 394 (2) 221-226
    CrossrefPubMedGoogle Scholar
  • 75 Nnanna II, Ehis OJ, Sidiquo II, Nnanna IG, Adekunle O. Serum procalcitonin: Early detection of neonatal bacteremia and septicemia in a tertiary healthcare facility. N Am J Med Sci 2011; 3 (3) 157-160
    PubMedGoogle Scholar
  • 76 Adib M, Bakhshiani Z, Navaei F, Saheb Fosoul F, Fouladi S, Kazemzadeh H. Procalcitonin: a reliable marker for the diagnosis of neonatal sepsis. Iran J Basic Med Sci 2012; 15 (2) 777-782
    PubMedGoogle Scholar
  • 77 Khoshdel A, Mahmoudzadeh M, Kheiri S , et al. Sensitivity and specificity of procalcitonin in diagnosis of neonatal sepsis. Iranian J Pathol 2008; 3: 203-207
    PubMedGoogle Scholar
  • 78 Zahedpasha Y, Ahmadpour KM, Hajiahmadi M, Haghshenas M. Procalcitonin as a marker of neonatal sepsis. Iran J Pediatr 2009; 19: 117-122
    PubMedGoogle Scholar